Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,580.40
+13.870.89%
Number of Gainers:2
Number of Losers:4
Number of Flat:1
PE:- -
High:1,597.90
Open:1,574.18
Low:1,556.75
Close:1,566.53
Volume:58.15M
Turnover:4.74B
Market Cap:1.64T
Float Cap:1.58T

Loading ...

AlzeCure Pharma to Present at Redeye Neurology Day

Reuters
·
1 hour ago

Deutsche Bank Keeps Their Sell Rating on Novo Nordisk (0QIU)

TIPRANKS
·
1 hour ago

Pfizer (PFE) Receives a Hold from Berenberg Bank

TIPRANKS
·
1 hour ago

Pfizer is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
13 hours ago

BridgeBio to Present New Real-World Study Comparing Acoramidis vs Pfizer’s Tafamidis in ATTR-CM at HFSA 2026

Reuters
·
13 hours ago

Health Rounds: Experimental Approach May Eliminate Cold Storage Requirement for mRNA Vaccines

Reuters
·
13 hours ago

Novo Nordisk Probes Patient Priorities in German Hemophilia A Study

TIPRANKS
·
17 hours ago

Scotiabank Adjusts Pfizer Price Target to $33 From $30, Sector Outperform Rating Kept

MT Newswires Live
·
17 hours ago

Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race

TIPRANKS
·
17 hours ago

Lilly’s New Basal Insulin Candidate Clears Key Early Trial Milestone

TIPRANKS
·
17 hours ago

Moderately bullish activity in Pfizer with shares up 0.24%

TIPRANKS
·
17 hours ago

General Medicine Raises $120 Mln to Build the Healthcare Store

Reuters
·
Yesterday

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Yesterday

Pfizer Keeps Quarterly Dividend at $0.43 per Share, Payable Dec. 7 to Shareholders of Record as of Nov. 6

MT Newswires Live
·
Yesterday

Pfizer Declares Q4 2026 Dividend of $0.43 a Share

Reuters
·
Yesterday

Pfizer Declares Fourth-Quarter 2026 Dividend

THOMSON REUTERS
·
Yesterday

Pfizer - Declares Q4 2026 Cash Dividend of $0.43 Per Share Payable December 7, 2026

THOMSON REUTERS
·
Yesterday

Viking Therapeutics, Inc.: Reporting Results from Part 2 of Vanquish-1 Study in 2027

THOMSON REUTERS
·
Yesterday

Viking Therapeutics Announces Initiation of Vk2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

THOMSON REUTERS
·
Yesterday

NYSE Most Active Issues

Dow Jones
·
Yesterday